Aidi Injection as Adjuvant Drug Combined with Chemotherapy in Treatment of Breast Cancer: A Systematic Meta-Analysis

Table 1

Characteristics of included studies.

First author	Year	No. E/C	Age	Stage	Surgery	Intervention
						Control group	Experimental group
Eisenhauer [16]	2016	40/39	46.73 ± 14.29/45.98 ± 15.78	III-IVa	Yes	CEF (6 cycles) : CTX 600 mg/m^2, d1, 8; EPI 100 mg/m^2, d1; 5-FU 500 mg/m^2, d1, 8; 21d	CT + Aidi 100 ml, qd, d1-8
Chen [17]	2012	30/26	42.5/42.5	II-III	No	AC-T (3 courses) : ADM 60 mg/m^2, d1+CTX 600 mg/m^2, d1; 14d, for 4 cycles; followed by TAX 175 mg/m^2, d1, 14d, 4 cycles	CT + Aidi 100 ml, qd, 4d
Chen [18]	2010	28/20	36.2/37.5	I-IIIa	No	CTF (3 cycles) : CTX 400–600 mg/m^2, 5-Fu 400–600 mg/m^2, d1, 8; THP 40–50 mg/m^2, d1; 21d	CT + Aidi 100 ml, qd, 10d
Fu [19]	2007	44/44	42/48	IV	No	NP (above 2 cycles) : NVB 25 mg/m^2, d1, 8; DDP 30 mg/m^2, d2-4; 28d	CT + Aidi 50 ml, qd, d 1–15
Dang [20]	2014	64/64	46.7 ± 20.3	Not clear	Yes	CEF (6 cycles) : CTX 600 mg/m^2, d1, 8; EPI 100 mg/m^2, d1; 5-FU 500 mg/m^2, d1, 8; 21d	CT + Aidi 100 ml, qd, d1-8
Gao [21]	2013a	32/32	33–69	III-IV	No	TAC (at least 2 cycles): TXT 75 mg/m^2, d1; EPI 90 mg/m^2, d1; CTX 500 mg/m^2, d1; 21d	CT + Aidi 80 ml, qd, d1-15
Gao [21]	2013b	16/16	33–69	III-IV	No	GEM + CAPE (at least 2 cycles)：GEM 1 g/m^2, d1, d8; CAPE 1 g/m^2, bid, d1-14; 21d	CT + Aidi 80 ml, qd, d1-15
Han [22]	2016	60/60	53.9 ± 11.5/54.2 ± 12.1	Not clear	Yes	CAF/CEF/TAC (6 cycles)	CT + Aidi 100 ml, qd
Jin [23]	2005	50/50	45	II-III	No	CEF (2 cycles): CTX 600 mg/m^2, d1, 8; EPI 75 mg/m^2, d1; 5-FUDR 750 mg, d1, 8; 21d	CT + Aidi 100 ml, qd, d1-15
Liu [24]	2006	32/20	46.2 ± 2.6/44.5 ± 3.2	I-IIIa	No	CEF (3 cycles): CTX 400–600 mg/m^2, 5-FU 400–600 mg/m^2, d1, 8; EPI 75–90 mg/m^2, d1; 21d	CT + Aidi 100 ml, qd, 10d
Li [25]	2012	24/28	57.2 ± 3.5/55.7 ± 3.4	IIb-III	No	TAC (2 cycles) : TXT 75 mg/m^2, d1; EPI 100 mg/m^2, d1; CTX 600 mg/m^2, d1; 21d	CT + Aidi 80 ml, qd, d1-15
Lu [26]	2005	60/40	39.5 (20–68）	II-III	No	CMF (3 cycles) : CTX 600 mg/m^2, d1, 8; MTX 30 mg/m^2, d1; 5Fu 500 mg/m^2, d1, 8; 21d	CT + Aidi 80 ml, qd, d1-15
Ren [27]	2013	26/22	42.3/42.2	II-III	No	TC-P (3 courses): THP 60 mg/m^2, d1, CTX 600 mg/m^2 d1, 14 d/cycle, for 4 cycles; followed by TAX 175 mg/m^2, d1, 14d, 4 cycles	CT + Aidi 100 ml qd, 4d
Shen [28]	2006	48/48	51/50	IV	No	CAF or TA (2 cycles): CAF : CTX 600 mg/m^2, d1, THP 40 mg/m^2, d1; 5-FU 750 mg, d1, d8; 21d. TA : Taxol 135 mg/m^2, d1; THP 40 mg/m^2, d1; 21d	CT + Aidi 50 ml d1-15
Song [29]	2012a	38/41	53.28 ± 11.32/53.02 ± 11.37	Not clear	Yes	CAF/CEF/AC/AT/TAC (6 cycles)	CT + Aidi 50 ml, qd
Song [29]	2012b	32/41	52.67 ± 11.85/53.02 ± 11.37	Not clear	Yes	CAF/CEF/AC/AT/TAC (6 cycles)	CT + Aidi 100 ml, qd
Wang [30]	2016	21/21	46.5 (33–67)	IV	No	NP (at least 2 cycles): NVB 25 mg/m^2, d1, d8; DDP 30 mg/m^2, d2, 4; 28d	CT + Aidi 50 ml, qd, d1-15
Wang [31]	2004	31/28	53.5 (31–70)/54.2 (32–69)	IV	No	NT (at least 2 cycles): NVB 25 mg/m^2, d1, 8; THP 40–50 mg/m^2, d1; 21	CT + Aidi 50 mg, qd, d1-15; 21d
Yang [32]	2005	30/30	48.4 (31–67)/47.6 (30–65)	III-IV	No	CAF (2 cycles): CTX 600 mg/m^2, d1, 8; ADM 50 mg/m^2, d1; 5-FU 500 mg/m^2, d1, 8; 21d	CT + Aidi 100 ml, qd, d1-10
Yang [33]	2016	36/37	53 (41–67)/54 (38–69)	III-IV	No	TXT + CAPE (6 cycles): TXT 75 mg/m^2, d1; CAPE 900 mg/m^2, bid, d1-14; 21d	CT + Aidi 100 ml, d1-14

CT = chemotherapy; E/C = experimental group/control group; 5-FU = 5-fluorouracil; TAX = paclitaxel; NVB = vinnorelbine; DDP = cisplatin; ADM = adriamycin; CTX = cyclophosphamide; EPI = epirubicin; ADM = adriamycin; THP = pirarubicin; TXT = docetaxel; 5-FUDR = floxuridin; GEM = gemcitabine; CAPE = capecitabine. Gao Qinghua 2013a were among the treatment-native patients; Gao Qinghua 2013b were among the patients failed in treatment with anthracycline and paclitaxel.